These are typical for GWAS results. Although localization is imprecise, the associated genomic regions are clearly informative as they implicate salient biological pathways (54), specific genomic features (55), and targets of common psychiatric medications (41, 45). Connecting most or all of the findings to specific genes requires additional data based on the function of the human brain; e.g., brain gene expression in brain regions (56), DNA-DNA looping (53), and epigenomics (57). The NIMH has funded the psychENCODE consortium (57) to conduct an array of functional genomic assays on brain samples from people with severe psychiatric disorders to enable this work. We anticipate considerable progress in this area in the near future.
